The predictive value of nutritional deficiency in the treatment of patients with locally advanced stomach cancer


DOI: https://dx.doi.org/10.18565/pharmateca.2019.12.9-14

N.A. Brish (1), T.Yu.Semiglazova (1, 2), P.A.Zakharova (1), A.V.Mishchenko (1), B.S.Kasparov (1), S.A. Protsenko (1), G.M.Teletaeva (1), D.Kh.Latipova (1), A.I.Semenova (1), E.V.Tkachenko (1), Yu.V.Alekseeva (1), Ya.A. Ulyanchenko (1), L.V.Filatova (1), V.V. Semiglazov (1, 3)

1) N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia; 2) North-Western State Medical University n.a. I.I. Mechnikov, St. Petersburg, Russia; 3) Pavlova First St. Petersburg State Medical University, St. Petersburg, Russia
Stomach cancer (SC) is one of the oncological diseases characterized by an extremely unfavorable prognosis. The disease is accompanied by a number of serious complications, including various disorders of metabolic processes, which undoubtedly leads to a deterioration of the general somatic status of patient, adversely affect the tolerability of specialized treatment, quality of life and longevity. Correction and/or maintenance of nutritional status (NS) in cancer patients is an important factor, which plays a significant role in increasing the effectiveness of antitumor treatment. The evaluation of NS and the programs for correcting its disorders in oncological patients are associated with a number of unresolved issues: in many countries, the protocols for diagnosing and correcting nutritional deficiencies have significant differences; possession of skills and methods for evaluating NS in patients are not mandatory for oncologists; not all of the standards for assessing NS are available for use in routine clinical ractice; there are some difficulties in the implementation of programs for providing formulas necessary for the correction of malnutrition in cancer patients not only in outpatient settings, but often also in the hospital.
Keywords: stomach cancer, nutritional status, nutritional deficiency (malnutrition), nutritional support

About the Autors


Corresponding author: Tatyana Yu. Semiglazova, MD, Associate Professor, Head of the Department, Leading Researcher at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, N.N. Petrov National Medical Research Center of Oncology; Professor at the Department of Oncology, North-Western State Medical University n.a. I.I. Mechnikov, St. Petersburg, Russia; e-mail: tsemiglazova@mail.ru
Address: 68, Leningradskaya Street, Pesochny settlement, St. Petersburg 197758, Russian Federation


Бионика Медиа